Clinical Trial

Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy

Study acronym: FIL_Tisle-HL
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, prospective, non-randomized, open-label, phase 2 clinical study to evaluate the efficacy and safety of tislelizumab in patients with de novo Hodgkin Lymphoma deemed ineligible to frontline chemotherapy.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-08-03; most recent amendment 2025-12-01.
Status change: Not Yet Recruiting → Recruiting 2024-07-18
Trial Details
NCT Number NCT05977673
Lead Sponsor Fondazione Italiana Linfomi - ETS
Conditions Hodgkin Lymphoma
Enrollment 28 participants
Start Date 2024-05-23
Primary Completion 2027-11 (estimated)
Study Completion 2029-11 (estimated)
Updated on ClinicalTrials.gov 2025-12-08